Biotech Week

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Week


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Aarhus University Hospital

New findings from Denmark, the the Netherlands and Belgium in the area of melanoma described

Study 1: Progression of metastatic melanoma was reduced by intratumoral injections of C Cure 709.

According to a study from Denmark, "We did a phase I dose-escalation trial to evaluate the feasibility and safety of intratumoral injections of C Cure 709, an allogeneic, continuous CTL cell line that, restricted by HLA-A2, recognizes MART-1-positive tumor cells through transduction with a T-cell receptor encoding gene. Cells were administered intratumorally in 4 dose levels ranging from 10⁸ to 10⁹ cells/d on days 1, 4, 7, 10, 14, and 28 of...

• View Other Issues of Biotech Week
  
• View Other NewsRx Publications